bluuebunny/crossref_metadata_2025_split huggingface dataset:
948 – Homocysteine And Cognitive Impairment In Chronic Kidney Disease
Authors: Yeh Y.-C. , Kuo M.-C. , Hwang S.-J. , Hsioa S.-M. , Tsai J.-C. , Huang M.-F. , Chen C.-S. 
Published: July 2013

ObjectivePatients with chronic kidney disease (CKD) have more cognitive impairments. However, the etiologies are not fully clear. Plasma homocysteine levels and vascular burden rise in CKD; meanwhile, high homocysteine levels and vascular factors are known risk factors of dementia in non-CKD patients. Thus, we aimed to investigate the association between homocysteine, vascular burden and cognitive impairment in CKD and to see if the effect of elevated homocysteine on cognitive impairment mediated by vascular factor.Methods146 patients with CKD and 69 normal comparisons were recruited. Cognitive function was evaluated by comprehensive neuropsychological tests assessing processing speed, executive function, language, visuospatial function, memory, and attention domains. Vascular burden was assessed by Framinghan cardiovascular risk scale (FCRS) which indicates risk of atherosclerotic diseases including stroke.ResultsIn controlled analysis, patients with CKD had lower scores in all cognitive domains, and had higher homocysteine levels (18.5±6.4 vs. 9.8±2.9, p< 0.0001) and FCRS(17.0±4.7 vs. 14.0±4.7, p< 0.0001). Among patients with CKD, higher homocysteine levels (p=0.026) were associated with lower score on digit symbol task which is related to processing speed and executive function with controlling for age, sex, education and stage of CKD. The association persisted (p=0.047) after controlling for vascular risks.ConclusionPatients with CKD had extensive cognitive impairments. Elevated homocysteine levels may be an risk factor, which is independent of vascular burden, of cognitive impairment on processing speed and executive function. Further studies to investigate if normalization of homocysteine can improve cognitive function will be suggested.
949 – Cannabis Use And Corpus Callosum (cc) Microstructural Integrity In Patients With First Episode Psychosis: a Diffusion-tensor Imaging (dti)-tractography Study
Authors: Rigucci S. , Reis-Marques T. , Di Forti M. , Taylor H. , Dell’Acqua F. , Mondelli V. , Bonaccorso S. , Simmons A. , David A.S. , Girardi P. , Pariante C.M. , Murray R.M. , Dazzan P. 
Published: July 2013

IntroductionThe impact of cannabis use on brain structure, particularly white matter (WM), is poorly understood. The CC is the largest WM structure in the brain. Abnormalities revealed in the CC may underlie functional anomalies of cannabis use. This is the largest study to explore the effect of cannabis on callosal WM connectivity among first episode psychosis (FEP) and controls.ObjectivesTo investigate the relationship between cannabis use and WM micro-structural integrity of the CC, in FEP and healthy controls.MethodsWe evaluated 56 FEP patients (67% current cannabis users), and 43 healthy controls (44% current cannabis users). We used Diffusion Tensor Imaging combined with a WM mapping-tractography technique to investigate the microstructural integrity of the CC.ResultsTotal CC Fractional anisotropy (FA) was lower in patients than controls (p=0.05). Cannabis-using patients had lower FA of the total CC than cannabis-using controls (p=0.04). There were no differences in FA between cannabis-using patients and those who had never used. However, cannabis-using patients had higher mean diffusivity (MD) of total CC (p= 0.02), Rostral-Body (p=0.003), Anterior Mid-Body (p=0.03) and the Splenium (p=0.06) than patients who never used cannabis. There were no differences in MD between patient users who started before the age of 16 and those who started later.ConclusionCannabis is associated with a significant effect on callosal WM integrity only in patients with psychosis. Disturbed callosal connectivity may explain some of the abnormalities with regard to the functional and clinical outcomes in FEP cannabis users, including measures of cognitive impairment.
951 – Audit Of The Introduction Of Agomelatine In a District General Hospital
Authors: Odelola A. , Goli A. , Etuk E. , Ugwunze N. , Riaz I. 
Published: July 2013

IntroductionAgomelatine is a novel antidepressant which was licensed in the United Kingdom in February 2009, but has not yet been included in national prescribing guidelines in the UK. The cost of Agomelatine and the need for monitoring of liver function during treatment have informed the development of strict local guidelines in respect of the initiation of Agomelatine.ObjectiveTo assess the use of Agomelatine following introduction in a district general hospital outpatient setting.AimsTo determine whether Agomelatine use is in accordance with recently formulated local guidelines and to explore prescribing patterns for Agomelatine.MethodCase notes were reviewed for consecutive patients prescribed Agomelatine over a 3 month study period. Using a specifically designed proforma, prescribing data, laboratory indices, outcome data and patient feedback were assessed against standards derived by consensus based on new prescribing guidelines.Results27 patients were studied. Agomelatine was initiated in 93% of cases for major depressive disorder as third-line treatment. 89% of patients completed baseline liver function tests and 63% had these reviewed at all of 3 time-points as recommended. 14% did not require an increment to the 50mg dose. 33% discontinued Agomelatine. 44% experienced mild side-effects such as headaches and nausea. 56% did not require an additional anxiolytic and 14% were successfully discharged. Positive feedback was obtained verbally and with rating scales.ConclusionsInitiation of agomelatine in accordance with recommended standards proved possible in a district general hospital setting. Agomelatine was well tolerated and positive patient feedback was received.
956 – History Of Suicidal Behavior And Analgesic Use In Community-dwelling Elderly
Authors: Olié E. , Courtet P. , Poulain V. , Ritchie K. , Artero S. 
Published: July 2013

BackgroundAnalgesics are easily obtainable and frequently used as a means of suicide. Elderly persons are high consumers of analgesics, notably opiods and also have a high suicide risk.AimTo determine whether elderly persons with a history of suicide attempts have higher rates of analgesic use compared to depressed and normal controls.Methods857 non-institutionalized individuals without dementia from a cohort of community-dwelling persons aged over 65 years (the ESPRIT study) were randomly selected from electoral rolls and divided into three groups: 41 subjects with a lifetime history of suicide attempts (SA), 410 affective controls (AC) with a history of depression without suicide attempts, and 406 healthy controls (HC). Data on socio-demographic and clinical characteristics including analgesic use (based on data from the national healthcare insurance scheme over 3 year follow up) were collected. Logistic regression was used to compare analgesic consumption by grade (I: non opioid drugs; II: opioid drugs) in the three groups.ResultsAfter controlling for gender, age, education, chronic disease, hospitalization, living alone and subjective health, opioid consumption was observed to be significantly higher in both SA and AC in comparison to HC (respectively: OR=2.33 [1.15-4.73] and OR=1.39 [1.01-1.91]). After exclusion of cancer cases, the relationship remained significant only for the SA group.ConclusionsOur findings suggest that suicidal vulnerability may be associated with an increased sensitivity to pain.
957 – Post Hoc Comparison Of The Efficacy Of Lisdexamfetamine Dimesylate And Osmotic-release Oral System Methlyphenidate In Children And Adolescents With Adhd
Authors: Coghill D. , Banaschewski T. , Lecendreux M. , Soutullo C. , Johnson M. , Zuddas A. , Anderson C. , Civil R. , Higgins N. , Bloomfield R. , Squires L. 
Published: July 2013

IntroductionIn a European, phase 3 study (SPD489-325), lisdexamfetamine dimesylate (LDX) and osmotic-release oral system methylphenidate (OROS-MPH) were more effective than placebo in improving core symptoms in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).Objectives and aimsTo compare post hoc the efficacy of LDX and OROS-MPH in study SPD489-325.MethodsThis 7-week, randomized, double-blind, parallel-group, dose-optimized, placebo-controlled trial enrolled patients aged 6-17 years with ADHD of at least moderate severity. Patients were randomized (1:1:1) to receive a once-daily dose of LDX (30, 50, 70 mg/day), OROS-MPH (18, 36, 54 mg/day) or placebo. Efficacy was assessed using the ADHD Rating Scale version IV (ADHD-RS-IV) and the Clinical Global Impression-Improvement (CGI-I) scale. Endpoint was defined as the last ontherapy treatment visit with a valid assessment.ResultsThe full analysis set comprised 317 patients (LDX, n=104; placebo, n=106; OROS-MPH, n=107). The difference between LDX and OROS-MPH in least squares mean change (95% confidence interval [CI]) in ADHD-RS-IV total score from baseline to endpoint was statistically significant in favour of LDX (-5.6 [-8.4, -2.7]; p < 0.001; effect size, 0.541). The difference (LDX minus OROS-MPH) in the percentage of patients (95% CI) with an improved CGI-I score at endpoint was also statistically significant in favour of LDX (17.4 [5.0, 29.8]; p < 0.05).ConclusionsThis post hoc analysis indicated that LDX is significantly more effective than OROS-MPH in improving core symptoms and global functioning in children and adolescents with ADHD.Supported by: Funding from Shire Development LLC.
963 – The Effect Of Ssris On Hot Flashes In Women With Perimenopausal Depression
Authors: Karaoulanis S.E. , Rizoulis A.A. , Angelopoulos N.V. 
Published: July 2013

ObjectiveMenopause is characterized by a decline in ovarian function resulting in vasomotor symptoms. Vasomotor symptoms include hot flashes and night sweats.The purpose of this study was to examine the effect of SSRIs on hot flashes in perimenopausal women with depression.Material and methodsSixty five perimenopausal women participated in this study. The subjects included 41 perimenopausal women with depression and 24 healthy women. The diagnosis of depression was made by a psychiatric interview and with the help of Hamilton Depression Rating Scale 17 (HAM-D 17). Hot flashes were examined with the use of Menopause Rating Scale (MRS) and they were divided as absent, mild, moderate, severe and very severe.ResultsPerimenopausal women were divided in three groups. The first group consisted of normal controls, the second of depressed perimenopausal women who were taking SSRIs and the third of depressed women not taking SSRIs. The control group had fewer hot flashes than the other two groups (p< 0.0001).The two groups of depressed women did not show any statistically significant difference in the presence and severity of hot flashes in relation to the use of SSRIs.ConclusionsIt was found that depression is associated with the presence of hot flashes in perimenopausal women. On the other hand the use of SSRIs did not relieve perimenopausal women with depression of hot flashes. Therefore, it seems that hormonal replacement therapy has the first role in the treatment of vasomotor symptoms in perimenopausal women.
964 – Cost-consequences Of Adjunctive Therapy With Pregabalin In Generalized Anxiety Disorder Patients With Partial Response To Ssri Treatment In Clinical Practice
Authors: Carrasco J.L. , Olivares J.M. , Álvarez E. , Pérez M. , López-Gómez V. , Rejas J. 
Published: July 2013

AimTo analyze the effect of adjunctive therapy with pregabalin versus usual care (UC) on healthcare costs and clinical consequences in generalized anxiety disorder (GAD) patients with partial response (PR) to previous SSRI.MethodsPost-hoc analysis of patients enrolled in a prospective 6-month observational study. Patients with a PR [CGI score >3 and insufficient response with persistence of anxiety symptoms (HAM-A score ≥16)] to SSRI monotherapy were considered eligible for inclusion. Two groups (based on psychiatrist judgment) were analyzed 1) adding pregabalin (150-600 mg/day) to existing therapy; or 2) UC (switching to a different SSRI or adding another anxiolytic. Costs estimation used year-2009 prices for GAD related healthcare resources utilization. Measures of clinical consequences were, changes in total scores of anxiety in HAM-A (primary outcome) and GAD co-morbid depressive symptoms in MADRS (secondary outcome) scales.ResultsFour-hundred-eighty-six newly prescribed pregabalin and 239 UC GAD patients [mean (SD) HAM-A 26.7 (6.9) and CGI 4.1 (0.5)] were analyzed. Adding pregabalin was associated with significantly higher adjusted mean changes (95% CI) vs. UC in HAM-A [-11.2 (-12.2;-10.2) vs. -14.9 (-15.6;-14.2), respectively; p< 0.001] and MADRS [-7.8 (-8.7;-6.8) vs. -11.6 (- 12.2;-10.9), respectively; p< 0.001]. Adjusted mean baseline healthcare costs were significantly reduced in both cohorts; -€487 (-652;-317) and -€531 (-648;-413), respectively (both p< 0.001), yielding to similar 6-month costs; €1543 (1375;1711) UC and €1497 (1380;1614) pregabalin, p=0.661.ConclusionIn this post-hoc analysis, GAD patients with PR to SSRI experienced greater symptom improvement with adjunctive therapy with pregabalin versus UC without increasing healthcare cost.
966 – Cortisol Awakening Response (car) In Adults With Attention Deficit Hyperactivity Disorder (adhd)
Authors: Corominas M. , Ribes V. , Palomar G. , Ramos-Quiroga J.A. , Ferrer R. , Catalan R. , Lopez-Craver M.V. , Olivares B. , Caballero A. , Corral N. , Casas M. 
Published: July 2013

IntroductionADHD in adults is associated with a significant impairment in many life activities increasing the risk of chronic stress in everyday life. Previous studies reported normal cortisol awakening response (CAR) in children with ADHD without comorbidities, nevertheless there is a lack of studies in adults.The aim of the present research is to examine CAR in adults with ADHD and to assess possible differences between the combine and inattentive subtypes.MethodologyPatients were recruited from the Program for adults with ADHD in the Department of Psychiatry of the Hospital Universitari Vall d’Hebron. The clinical sample consisted of 50 adults, age between 18 and 51 years (mean 35.24 ± 9.21) fulfilling current diagnostic criteria for ADHD (DSM-IV criteria). All patients were naïve to stimulant medication. Psychiatric and organic comorbid disorders were excluded. To assess CAR, four salivary cortisol samples were collected at 0, 30, 45 and 60 minutes after awakening.ResultsThe mean increase in CAR for the whole group of patients was 10.34±8.79 nmols/l. T-test comparisons showed no significant differences in the mean increase of CAR between the inattentive (mean: 9.47±9.04 nmols/l) and combine (mean: 11.25±8.67 nmols/l) subtypes (t=0.610; z=0.546).ConclusionDespite there were no significant differences in salivary CAR between ADHD subtypes in adults, the mean increase of CAR was higher in combine than in the inattentive subtype. Salivary CAR needs to be further explored as an index of vulnerability to stress in these patients.
974 – Psychological Health And Quality Of Life Of Children And Adolescents With Short Stature
Authors: Bullinger M. 
Published: July 2013

Introduction and aimsFindings regarding impairments in quality of life of children and adolescents with short stature are not unequivocal. The present paper examines prevalence of such impairments, their mutual relationship, potential determinants and differences between patient self-report and parent report.MethodsChildren and adolescents (n=218) with short stature (idiopathic short stature and growth hormone deficit) and their parents provided assessments of psychological health (Strengths and Difficulties Questionnaire - SDQ) and health related quality of life (KIDSCREEN Questionnaire). Variance and regression analysis were used to identify group differences and potential determinants of quality of life.ResultsChild-reported SDQ total score was in the normal range in over 80% of cases, while 7.8% were identified as borderline impaired and 8.2% were classified as abnormal. Parents ratings were 76% normal, 8.6% borderline and 17.8% abnormal. Impairments were found for young children, for boys and for very short patients. Analysis of variance showed higher KIDSCREEN scores in the SDQ normal group. SDQ and KIDSCREEN correlated significantly. Half of the variance in KIDSCREEN scores was explained by a combination of SDQ scores, clinical status and sociodemographic data in child and parent samples.ConclusionParents reported higher impairments in psychological health than children. SDQ related differences in KIDSCREEN scores and the proportion of variance in QoL explained by the SDQ suggest that mental health should be routinely assessed in children with short stature as a part of the diagnostic process. Psychological interventions should be considered when clinically indicated.
985 – ADHD And Atopy Are Related: An Exploratory Study On 102 Children
Authors: Lehéron C. , Morin A.J.S. , Caci H. 
Published: July 2013

IntroductionScarce studies have reported a relationship between Attention Deficit-Hyperactivity Disorder (ADHD) and atopic symptoms (i.e. rhinitis, eczema), food allergy and asthma in children and adults. Results of the studies show a trend toward a positive relationship.AimsThis study aims to explore the relationship between ADHD and atopy in treatment-naïve children referred to an ADHD consultation.MethodsFor 12 consecutive months, all children diagnosed with impairing ADHD and for who a psychopharmacological treatment was indicated were blood tested for the presence of a mixture of specific IgE (PHADIATOP® test). An allergist subsequently performed prick-tests on only those with positive tests.Results63 children out of 102 included (61.8%) had a positive blood test. Age, gender and Body Mass Index did not differ between positive and negative groups. Children were more likely to have ADHD Combined (66/102). Rates of Opponent Defiant Disorder (ODD, 40/102) and Conduct Disorder (CD, 14/102) were similar between groups. Atopy is not with ODD or CD. Familial history of ADHD (36/102) or atopy (39/102) is significant. Prick tests confirmed the blood test in all cases. Rhinitis was most frequent (40/63) with moderate to severe intensity in 23 cases (67.7%), associated with a history of conjunctivitis in 21 cases (61.8%). Most youths had never been referred to an allergist although some of them had a persistent and severe symptomatology.ConclusionThis is the larger study reporting a strong relationship between ADHD and atopy. All children referred for ADHD shall be screened for atopy and vice versa.
986 – Early Recovery Experiences Of Patients After An Unexpected Cardiac Surgery: a Preliminary Study
Authors: Chang Y.L. , Tsai Y.F. 
Published: July 2013

AimThe aim of this study was to understand the early stage of illness recovery experiences and related needs of patients who underwent emergency cardiac surgery.MethodsA qualitative approach was used. Patients who had been transferred from intensive care units to a general ward for least 6 days and were expecting to be discharged within one week were interviewed at a medical center in northern Taiwan.ResultsA total of 9 patients participated in this study. Two themes emerged from the analysis related to their illness experiences. Patients felt ‘shock’ when they were informed to have emergency surgery or when they woke up to know surgery had been done on them, including unbelieving and suspicious. They also described various degree of ‘psychiatric symptoms’, such as fragment of memory or memory loss related to the medical procedure, nightmares, insomnia,hallucinations, derealization, daze, sluggish response, and attention deficit. Three themes emerged from the analysis looking at their needs. Patients described the needs for ‘reassurances,’ ‘support,’ and ‘more information about subsequent treatment and care’ to rebuild their new life in the future.ConclusionThis study has shown that these patients had many of symptoms related to acute stress and their related needs in the early recovery stage. The findings would enhance the health professions can design early interventions to treat acute stress symptoms in critical care units. It would help patients in the restore their social and occupational functions, and prevent the development of PTSD. It is suggested integrated interdisciplinary care and support are crucial helping patients recovery.
990 – Adolescent Sexual Abuse: From Incest To Hebephilia
Authors: Vannucci C. , Cano J.-P. 
Published: July 2013

IntroductionOn the eve of its entry into the DSM-V, hebephilia is a sexual deviance under debate. Few studies describe hebephiles, then who are these sex offenders?ObjectivesAssess the profile of adolescents sex offenders and their victims, and the characteristics of their penal treatment.MethodsThis is a retrospective study carried out from the court records of adolescents sex offenders followed by the State Department on the Enforcement of Sentences of Tours and Chateauroux (France).Results31 offenders and 57 victims have been identified.-Concerning offenders: the average age was 37.8 ± 9.4 years. 71% had a job and 51.6% lived in couple. 87.1% had normal or borderline intellectual level. 38.7% had been victimized in childhood, of which 58.3% had experienced sexual violence.-Regarding penal treatment: 42% of subjects were judged by a correctional court, and 58% by a criminal court. 22.6% of subjects were in recidivism. The average length of imprisonment was 7.5 ± 4.2 years. 67.8% of subjects were sentenced to treatment with 48.4% imposed an injunction care. The average duration of treatment was 4.4 ± 3.1 years.-Concerning victims: 57 victims were identified of which 86% were female. The mean age was 14.1 ± 2.1 years. 58.1% of violences experienced were rapes in with 48.4% of intrafamilial. 67% of violence had repeated character.ConclusionThis French study in which data are comparable to those of the North American literature, provides details on the characteristics of hebephiles that are passed to the act.
992 – Efficacy Of Paliperidone Er In Patients With Psychotic Symptoms
Authors: Medina Ojeda G. , Blanco Garrote J.A. , Agundez Modino A. , Arribas Simon B. , Franch Valverde J.I. 
Published: July 2013

ObjectiveTo evaluate the efficacy of paliperidone ER in patients with psychotic symptoms, assessing the improvement of positive and negative symptoms and functioning.MethodAn observational, prospective and multicentre study was carried out, collecting in a systematic way all the information after the prescription of paliperidone ER in patients with psychotic symptoms with a 12 weeks follow up. Baseline visit (V0), 15 day visit (V1), one month visit (V2), two month visit (V3) and three month visit (V4).The primary variable of efficacy used was the assessment of severity in symptoms with the ICG-S scale. Other variables of efficacy used were PANSS and ICG-C scales in all visits and PSP scale at baseline visit and final visit. At baseline visit medical and psychiatric history were collected.ResultsPaliperidone ER treatment was initiated in 26 patients with a mean age of 35.6 years old (SD 11.62). The main reason of treatment initiation with paliperidone ER was the lack of efficacy of other previous treatments in 12 patients (46.15%), followed by lack of tolerability in 5 patients (19.23%). The used dosage ranged between 3 and 18 mg/day, mean dosage of 8.28 (SD 3.16). There was a statistically significant decrease of the PANSS scores throughout the study in positive, negative and global symptoms .There was also a statistically significant reduction of ICG and PSP scores throughout the study.ConclusionsPaliperidone ER was effective in the treatment of the psychotic symptoms on both positive and negative symptoms and also in functioning.